Botulinum toxin A - Daewoong Pharmaceuticals

Drug Profile

Botulinum toxin A - Daewoong Pharmaceuticals

Alternative Names: DWP-450; Evosyal; Nabota

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Daewoong Pharmaceutical
  • Developer ALPHAEON Corporation; Daewoong Pharmaceutical; Evolus
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glabellar lines
  • Phase III Muscle spasticity
  • Phase II/III Blepharospasm; Facial-wrinkles

Most Recent Events

  • 01 Nov 2016 Evolus completes a phase II trial in Glabellar lines in USA (NCT02428608)
  • 01 Oct 2016 Phase-II/III clinical trials in Blepharospasm in South Korea (Parenteral) (NCT02947815)
  • 01 Aug 2016 Phase-II/III clinical trials in Facial wrinkles in South Korea (Parenteral) (NCT02882893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top